Bayer | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Rubbish bin junk trash

Regulatory Trial results

9 November 2023

Another PI3K inhibitor bites the dust

Conferences Trial results

5 October 2023

Triple data take Nuvalent's market cap above $3bn

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

Trial results

18 September 2023

Bayer looks to clinical validation for $1.5bn Vividion deal

Subscribe to Bayer